COMPANY
Shasqi
Funding and NIH signals
- NIH award NIH awarded $1.14M (SBIR Phase II 5R44CA306491-02, continuation, notice Aug 18, 2026). NIH RePORTER 5R44CA306491-02 (Aug 18, 2026)
Evidence (1 event)
- Aug 18, 2026 · NIH RePORTER 5R44CA306491-02
Organization: SHASQI, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44CA306491-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1142054; Administering IC: National Cancer Institute; Project title: CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry; Organization type: Domestic For-Profits
- Aug 18, 2026 · NIH RePORTER 5R44CA306491-02
Timeline
- Grant Government grant — SBIR: $1.14M (annual award, as published), announced Aug 18, 2026. Agency: NIH/NCI. Source: government award database. source ↗
- Grant Government grant — SBIR: $1.09M (annual award, as published), announced Sep 24, 2025. Agency: NIH/NCI. Source: government award database. source ↗
- Grant Government grant — SBIR: $431,859 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NCI. Source: government award database. source ↗
- Grant Government grant — SBIR: $1.21M (annual award, as published), announced Jun 28, 2025. Agency: NIH/NCATS. Source: government award database. source ↗
- Trial start 1: Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors source ↗
Funding
- Government grant — SBIR: $1.14M (annual award, as published), announced Aug 18, 2026. Agency: NIH/NCI. Source: government award database. source ↗
- Government grant — SBIR: $1.09M (annual award, as published), announced Sep 24, 2025. Agency: NIH/NCI. Source: government award database. source ↗
- Government grant — SBIR: $431,859 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NCI. Source: government award database. source ↗
- Government grant — SBIR: $1.21M (annual award, as published), announced Jun 28, 2025. Agency: NIH/NCATS. Source: government award database. source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04106492 | Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | 1 | Terminated | Aug 1, 2020 | Sep 7, 2023 (actual) |